The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -30,051,977 |
| Stock compensation expense | 6,424,730 |
| Depreciation and amortization | 71,265 |
| Amortization of debt discount | 481,424 |
| Loss on share issuance to kineta separation payments | 185,019 |
| Change in fair value of holdback shares | -1,590,948 |
| Other current assets | -457,523 |
| Other noncurrent assets | -154,998 |
| Accounts payable and accrued expenses | -3,761,184 |
| Net cash flows from operating activities | -27,629,150 |
| Cash paid for kineta acquisition, net of assumed cash | 1,259,278 |
| Purchase of property and equipment | 76,083 |
| Net cash flows from investing activities | -1,335,361 |
| Series a preferred dividend | 8,356 |
| Repayment of assumed kineta indeptedness | 434,000 |
| Payments made on kineta severance promissory notes | 394,709 |
| Payments on equipment lease | 54,315 |
| Proceeds from bridge note | 3,000,000 |
| Payment of bridge note | 1,500,000 |
| Proceeds from issuance of common stock | 18,303,312 |
| Proceeds from warrants exercised | 3,620,657 |
| Payment of offering costs associated with issuance of common stock | 1,555,307 |
| Payment of merger transaction costs | 500,000 |
| Payment of net liabilities assumed in reverse recapitalization | 550,000 |
| Net cash flows from financing activities | 19,927,282 |
| Net change in cash and cash equivalents | -9,037,229 |
| Cash and cash equivalents at the beginning of the year | 12,657,178 |
| Cash and cash equivalents at the end of the year | 3,619,949 |
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)